Suppr超能文献

Analytical and clinical evaluation of two homogeneous assays for LDL-cholesterol in hyperlipidemic patients.

作者信息

Esteban-Salán M, Guimón-Bardesi A, de La Viuda-Unzueta J M, Azcarate-Ania M N, Pascual-Usandizaga P, Amoroto-Del-Río E

机构信息

Department of Biochemistry, Hospital de Galdakao, 48960 Vizcaya, Spain.

出版信息

Clin Chem. 2000 Aug;46(8 Pt 1):1121-31.

Abstract

BACKGROUND

LDL-cholesterol (LDL-C) concentrations are the primary basis for treatment guidelines established for hyperlipidemic patients. LDL-C concentrations are commonly monitored by means of the Friedewald formula, which provides a relative estimation of LDL-C concentration when the triglyceride concentration is <2000 mg/L and there are no abnormal lipids. The Friedewald formula has several limitations and may not meet the current total error requirement of <12% in LDL-C measurements.

METHODS

We evaluated the analytical and clinical performance of two direct methods (Roche and Wako) by analyzing 313 fresh serum samples obtained from dyslipidemic patients in a lipid clinic and comparing them with modified beta-quantification.

RESULTS

Both homogeneous assays displayed excellent precision (CV <2%). The Roche method showed a mean total error of 7.72%, and the Wako method showed a mean total error of 4.46% over a wide range of LDL-C concentrations. The Roche method correlated highly with the modified beta-quantification assay (r = 0.929; y = 1.052x - 168 mg/L; n = 166) and showed a bias of -4. 5% as a result of the assigned standard value. The Wako method also correlated highly with beta-quantification (r = 0.966; y = 0.9125x + 104.8 mg/L; n = 145) without significant bias. The Roche method correctly classified 97% of patients with triglycerides <2000 mg/L, 75% of patients with type IIb hyperlipemia (HPL), and 84% of patients with type IV HPL based on the cutpoints of 1300 and 1600 mg/L, compared with 98%, 78.4%, and 89%, respectively, for the Wako method. In dysbetalipoproteinemic patients, both methods have a 30% mean positive bias compared with beta-quantification.

CONCLUSIONS

Both direct methods can be a useful alternative when ultracentrifugation is not available for the diagnosis and control of lipid-lowering medication for patients with mixed HPL, but not for patients with type III hyperlipidemia.

摘要

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验